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New developments in radiotherapy (RT) and chemotherapy
(CT) are helping to improve the overall survival and cure rates
of patients with Hodgkin’s disease (HD). However, treatment-
related complications have taken on enormous clinical impor-
tance. As reported in most publications, these include injures of
the gastrointestinal tract, pulmonary function impairment, car-
diac toxicity, thyroid dysfunctions, sterility, immunity alterations
and the arising of second tumor.1–5 Second primary cancer (SPC),
particularly acute non-lymphoid leukemia (ANLL), non-Hodgkin’
lymphoma (NHL) and secondary solid tumours (ST), are well-
known late complications that can occur in patients treated for
HD.1,4,5 The increase of ANLL risk has been correlated with
host-related factors and the type of treatment procedures6 and
radiation-induced leukemia occurs after a period of time gener-
ally exceeding 5 years (Fig. 1). The risk is higher in patients treated
with combined RT and CT regimens including mechloretamine
and procarbazine.1,6
With regard to the occurrence of ANLL after RT alone, Cole-
man7 and of Hoppe8 has reported, respectively, only one case
(A.R. 0.6% at 10 years) of ANLL among 441 patients and 3 cases
(A.R. 0.5% at 10 years) among 898 patients treated with irradiation
alone. Valagussa et al.9 have reported that the ABVD is not asso-
ciated with acute leukemia occurrence even when combined with
radiation. In research carried out by the Cancer Institute in
Milan,9 only one case of ANLL was recorded after ABVD + RT, with
a Cumulative risk of 0.7% (at 15 years), compared with a risk of
9.5% (at 15 years) in patients treated with MOPP + RT (P = 0.04).
Further studies will make it possible to investigate the occurrence
of ANLL after RT + ABVD. Many authors4,6,10,11 are in accord on the
fact that a higher risk of leukemia from CT including alkylating
agents and procarbazine with or without irradiation, compared
to the risk factor involved in the use of ABVD or RT alone. Other
studies report the potential role of sex, age, splenectomy and
spleen irradiation as risk factors in ANLL occurrence.3,4,6
There is controversy regarding the role of splenectomy. Van
Leeuwen et al.12 have reported that splenectomy might predis-
pose to secondary ANLL. For other authors correlation does not
exist between splenectomy and onset of leukaemia.4,6 In conclu-
sion, treatment with MOPP alone and MOPP plus RT can increase
the risk of ANLL. Moreover, the problem of secondary leukemia is
probably linked with the prolonged survival of HD patients and
the risk of induced cancer is connected both with the type of
treatment received and with the related factors. It should also
be observed that these results refer to treatment carried out 20
or 25 years ago, when higher CT doses were used and larger vol-
umes of tissue were irradiated. Finally, we must continue to focus
attention on long-term survivors of HD patients, to modify our
treatment strategy and to identify types of treatment which do
not lead to undesirable effects in the future.
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SECOND SOLID CANCER AFTER HODGKIN’S DISEASE: ANALYSIS
OF THE RISK AND REVISION OF THE LITERATURE
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Ciaccio, Via Pio X, 88100 Catanzaro, Italy
At present time, patients with Hodgkin’s disease (HD) have a
high probability of cure. However, the late sequelae treatment-
related have a remarkable clinical importance. An increased of
second primary cancers (SPC) has been observed among long-
term survivors of HD: particularly, acute non-lymphoid leukemia
(ANLL), non-Hodgkin’ lymphoma (NHL) and secondary solid
tumours (ST).1–5 The increase of ANLL risk has been correlated
with host-related factors and the type of treatment procedures.1,5
Several authors have demonstrated that secondary ANLL was
likely with chemotherapy-treatment. NHL has been correlated
with the radiochemotherapy treatment: the risk has concentrated
in the first year following start of treatment and declined in the
subsequent 5 years.6 Recently, several studies have been focused
attention on the incidence of ST: the appearance risk increases
with the length of the follow-up (Fig. 1) and results correlated
with the kind of treatment using RT alone or in combination with
chemotherapy (CT ).1,4 The most frequent solid tumor are lung
cancer, breast cancer, melanoma skin, gastrointestinal cancer
and sarcoma of the bone.
On the occurrence of solid tumours in patients treated with CT
alone, the results of BNLI7 shows an increased risk of ST after CT
alone: further study is required for a better examination of the
increase in risk of ST after treatment with CT. Moreover, Maurizi
et al.4 show that additional therapy for relapsing patients with
CT + RT after initial therapy with RT alone does not increase the
risk of ST, while in a recent study8 the addition of combined ther-
apy for recurrent disease in patients previously treated with
radiotherapy showed a significant increase in the relative risk of
ST. In the authors’ opinion, it is possible that either the cumula-
tive dose of radiation received after secondary treatment with
CT was responsible for a high occurrence of ST or that the
increase in ST occurrence was due to initial radiation.
Age is the major risk factor of solid tumours in the HD popu-
lation, in the same way as age is a major risk factor of almost all
solid cancer in the general population. It is uncertain whether
this biological phenomenon is related to age or to the HD status
of patients or whether it is an undifferentiated effect of treatment
(RT or CT or CT + RT).
With respect to the location of ST, no definite relation could be
made between the treatment received (radiotherapy alone and
radiotherapy with chemotherapy) and the tumor tissue. For
example, lung cancer was observed more often in patients who
had received RT, but also in patients treated with CT alone. In
their detailed analysis of various solid tumours, Kaldor et al.9
have pointed out that the occurrence of lung cancer is higher in
long-term HD survivors than in the general population. They con-
clude that this higher risk is due to the cancer-inducing effects of
both CT and RT, compared with those produced by other risk fac-
tors, e.g. smoking for lung cancer. Van Leeuwen et al.10studied a
cohort of 1939 patients treated for HD who developed 30 lung can-
cers and examined the relationship between the carcinogenic
effect of smoking and radiation. They conclude that the appear-
ance of lung cancer is related both to the radiation dose received
by the lung and to smoking after radiation exposure.
Regarding the occurrence of breast cancer,Van Leeuwen
et al.11 and Yahalom et al.12 reported an increased risk of breast
cancer in women who have received radiation therapy for HD at
a younger age. Moreover, Yahalom et al.12 showed that breast can-
cer following the treatment for HD was bilateral and frequently
involved the medial half of the breast,while the prognosis of the
disease is similar to that of patients with primary cancer. In Han-
cock’s experience,13 the risk after 15 years is equivalent both in
women treated with RT alone and in women receiving RT com-
bined with MOPP. For other types of cancer such as cancer of
the gastroenteric tract, of the soft tissue and of the nervous sys-
tem, which have been observed in irradiation, there could be a
Fig. 1. Cumulative risk of solid tumour (ST).
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